NCT04549207Active, not recruitingPhase 4
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
A Randomised Trial Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (REaCT-Hold BMA)
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
The investigators propose to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA treatment in patients with bone metastases from breast cancer and castration-resistant prostate cancer
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (actual)
- First submitted
- 1 Sept 2020
- Start date
- 9 Oct 2020
- Primary completion date
- 17 Apr 2025
- Lead sponsor
- Ottawa Hospital Research Institute
- Diseases
- Prostate cancer
- NCT number
- NCT04549207
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 240
- From 9 Oct 2020 to the primary completion date, 17 Apr 2025
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Radiotherapy or surgery to the bone planned within 4 weeks after randomization
Other illness
- History of, or current evidence of osteonecrosis of the jaw
Lab values
- Current hypercalcemia defined as corrected serum calcium of \> 3 mmol/L (from standard bloodwork completed within one month prior to treatment dose)
Other
- Definite contraindication for BMA
Who the study is looking for
- Patients with either radiologically and/or histologically confirmed bone metastases from castrate resistant prostate cancer or breast cancer who are currently receiving BMA
- Patient has received BMA for 2 or more years counting from the first BMA dose for bone metastases
- Age 18 years or older
- Able to provide verbal consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| William Osler Health System Coordinator of this site? Confirm its status | Brampton | Canada | Unknown status |
| London Health Sciences Centre Coordinator of this site? Confirm its status | London | Canada | Unknown status |
| Southlake Regional Health Centre Coordinator of this site? Confirm its status | Newmarket | Canada | Unknown status |
| The Ottawa Hospital Cancer Centre Coordinator of this site? Confirm its status | Ottawa | Canada | Unknown status |
| Thunder Bay Regional Health Sciences Centre Coordinator of this site? Confirm its status | Thunder Bay | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.